

Hertzel C Gerstein

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1471997/hertzel-c-gerstein-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

422
papers

55,533
citations

95
h-index

232
g-index

473
ext. papers

64,011
ext. citations

11.8
avg, IF

7.45
L-index

#	Paper	IF	Citations
4 ²²	Effects of intensive glucose lowering in type 2 diabetes. <i>New England Journal of Medicine</i> , 2008 , 358, 2545-59	59.2	5809
4 ²¹	Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. <i>Lancet, The</i> , 2000 , 355, 253-259	40	2668
4 ²⁰	Effects of intensive blood-pressure control in type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , 2010 , 362, 1575-85	59.2	2411
4 ¹⁹	Effects of combination lipid therapy in type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , 2010 , 362, 1563-74	59.2	1940
4 ¹⁸	Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 286, 421-6	27.4	1695
4 ¹⁷	Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. <i>Lancet, The</i> , 2000 , 355, 773-8	40	1643
4 ¹⁶	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2015 , 373, 2247-57	59.2	1393
4 ¹⁵	The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. <i>Diabetes Care</i> , 1999 , 22, 233-40	14.6	1355
4 ¹⁴	Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. <i>Stroke</i> , 2001 , 32, 2426-32	6.7	1341
4 ¹³	Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. <i>Lancet, The</i> , 2006 , 368, 1096-105	40	1312
4 ¹²	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1994 , 271, 703	27.4	1292
4 ¹¹	Basal insulin and cardiovascular and other outcomes in dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 319-28	59.2	1138
4 ¹⁰	Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. <i>Annals of Internal Medicine</i> , 2001 , 134, 629-36	8	962
4 ⁰⁹	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2019 , 394, 121-130	40	917
4 ⁰⁸	Effects of medical therapies on retinopathy progression in type 2 diabetes. <i>New England Journal of Medicine</i> , 2010 , 363, 233-44	59.2	859
4 ⁰⁷	Intensive glucose control and macrovascular outcomes in type 2 diabetes. <i>Diabetologia</i> , 2009 , 52, 2288-98	20.3	854
4 ⁰⁶	Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). <i>Lancet, The</i> , 2000 , 356, 279-84	40	748

405	Long-term effects of intensive glucose lowering on cardiovascular outcomes. <i>New England Journal of Medicine</i> , 2011 , 364, 818-28	59.2	732
404	Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies. <i>Diabetologia</i> , 2005 , 48, 2460-9	10.3	676
403	n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 309-18	59.2	659
402	Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. <i>Circulation</i> , 2000 , 102, 1014-9	16.7	598
401	Effect of ramipril on the incidence of diabetes. <i>New England Journal of Medicine</i> , 2006 , 355, 1551-62	59.2	583
400	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1994 , 271, 389	27.4	553
399	Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. <i>Circulation</i> , 2007 , 115, 114-26	16.7	552
398	Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. <i>Anesthesiology</i> , 2014 , 120, 564-78	4.3	509
397	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1995 , 274, 1800	27.4	477
396	Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. <i>Diabetes Care</i> , 2007 , 30, 162-72	14.6	405
395	Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. <i>JAMA Cardiology</i> , 2018 , 3, 225-234	16.2	403
394	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1994 , 272, 1367	27.4	399
393	Ramipril and the development of diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 286, 1882-5	27.4	390
392	Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. <i>American Journal of Cardiology</i> , 2007 , 99, 21i-33i	3	385
391	Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. <i>Diabetes Research and Clinical Practice</i> , 2007 , 78, 305-12	7.4	384
390	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1994 , 271, 59	27.4	379
389	Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. <i>Lancet Neurology</i> , 2011 , 10, 969-77	24.1	356
388	Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <i>Diabetes Care</i> , 2010 , 33, 1578-84	14.6	342

387	Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 3668-76	5.6	328
386	Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. <i>Diabetes Care</i> , 2009 , 32, 221-6	14.6	314
385	The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. <i>BMJ, The</i> , 2010 , 340, b5444	5.9	313
384	Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. <i>Diabetes Care</i> , 2002 , 25, 1919-27	14.6	306
383	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum. <i>Diabetes Care</i> , 2018 , 41, 14-31	14.6	263
382	Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. <i>Lancet Diabetes and Endocrinology,the</i> , 2017 , 5, 431-437	18.1	258
381	Long-term consequences of fetal and neonatal nicotine exposure: a critical review. <i>Toxicological Sciences</i> , 2010 , 116, 364-74	4.4	254
380	Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. <i>Diabetes Care</i> , 2010 , 33, 1379-81	14.6	240
379	Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. <i>Diabetes Care</i> , 2012 , 35, 787-93	14.6	237
378	Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. <i>Diabetes Care</i> , 2005 , 28, 1630-5	14.6	236
377	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019 , 394, 131-138	40	228
376	Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. <i>Circulation</i> , 2003 , 108, 420-5	16.7	227
375	A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. <i>Diabetes Care</i> , 2007 , 30, 389-94	14.6	224
374	The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. <i>Diabetes Care</i> , 2010 , 33, 1859-64	14.6	217
373	Association between shortened leukocyte telomere length and cardiometabolic outcomes: systematic review and meta-analysis. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 82-90		216
372	Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). <i>Lancet, The</i> , 2001 , 358, 1147-53	40	215
371	Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. <i>Lancet Diabetes and Endocrinology,the</i> , 2014 , 2, 843-51	18.1	214
370	The DREAM trial [Authors' reply]. <i>Lancet, The</i> , 2006 , 368, 2050-2051	40	207

369	Risk factors for acute myocardial infarction in Indians: a case-control study. <i>Lancet, The</i> , 1996 , 348, 358-63	40	203
368	The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. <i>Diabetologia</i> , 2005 , 48, 1749-55	10.3	202
367	Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>Circulation</i> , 2006 , 114, 201-8	16.7	199
366	Albuminuria in chronic heart failure: prevalence and prognostic importance. <i>Lancet, The</i> , 2009 , 374, 543-50	40	191
365	Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. <i>Circulation</i> , 2005 , 112, 48-53	16.7	185
364	Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. <i>Diabetes Care</i> , 2014 , 37, 1721-8	14.6	179
363	Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. <i>Lancet, The</i> , 2010 , 376, 103-11	40	178
362	Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism?. <i>Journal of General Internal Medicine</i> , 1996 , 11, 744-9	4	172
361	Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. <i>European Heart Journal</i> , 2013 , 34, 3137-44	9.5	167
360	A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hypoglycemia in Type 2 Diabetes) Study. <i>Diabetes Medicine</i> , 2011 , 23, 731-40	3.5	167
359	The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>Archives of Internal Medicine</i> , 2008 , 168, 1699-704		165
358	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2017 , 5, 877-886	18.1	164
357	Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <i>American Journal of Cardiology</i> , 2007 , 99, 4i-20i	3	155
356	Computerized clinical decision support systems for chronic disease management: a decision-maker-researcher partnership systematic review. <i>Implementation Science</i> , 2011 , 6, 92	8.4	154
355	Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. <i>European Heart Journal</i> , 2011 , 32, 581-9	9.5	153
354	Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 2390-8	15.1	146
353	Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). <i>American Heart Journal</i> , 2008 , 155, 26-32, 32.e1-6	4.9	146
352	Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. <i>Circulation</i> , 2007 , 115, 1371-5	16.7	146

351	Individualized electronic decision support and reminders to improve diabetes care in the community: COMPETE II randomized trial. <i>Cmaj</i> , 2009 , 181, 37-44	3.5	145
350	Kidney disease after preeclampsia: a systematic review and meta-analysis. <i>American Journal of Kidney Diseases</i> , 2010 , 55, 1026-39	7.4	141
349	Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. <i>Diabetologia</i> , 2004 , 47, 1519-27	10.3	139
348	Dysglycaemia and risk of cardiovascular disease. <i>Lancet, The</i> , 1996 , 347, 949-50	4.0	134
347	Does a combination regimen of thyroxine (T4) and 3,5,3'-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 4551-5	5.6	133
346	Ethnic variation in adiponectin and leptin levels and their association with adiposity and insulin resistance. <i>Diabetes Care</i> , 2010 , 33, 1629-34	14.6	128
345	Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. <i>Diabetes Care</i> , 2016 , 39, 701-8	14.6	126
344	Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <i>American Journal of Cardiology</i> , 2007 , 99, 34i-43i	3	125
343	Incidence of postpartum thyroid dysfunction in patients with type I diabetes mellitus. <i>Annals of Internal Medicine</i> , 1993 , 118, 419-23	8	124
342	Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 42-49	6.7	121
341	The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial. <i>Diabetes Research and Clinical Practice</i> , 2002 , 55, 209-19	7.4	120
340	A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. <i>Diabetes Care</i> , 2010 , 33, 1176-8	14.6	118
339	Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. <i>JAMA Internal Medicine</i> , 2014 , 174, 324-33	11.5	112
338	Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. <i>Lancet, The</i> , 2014 , 384, 1936-41	4.0	111
337	Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 641-7	12.7	110
336	Adipocyte hypertrophy, fatty liver and metabolic risk factors in South Asians: the Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE). <i>PLoS ONE</i> , 2011 , 6, e22112	3.7	109
335	Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study. <i>Diabetes Care</i> , 2016 , 39, 780-7	14.6	104
334	Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. <i>Biochemical Journal</i> , 2015 , 468, 125-32	3.8	103

333	Prospective associations of vitamin D with β cell function and glycemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study. <i>Diabetes</i> , 2011 , 60, 2947-53	0.9	103
332	Fetal and neonatal exposure to nicotine in Wistar rats results in increased beta cell apoptosis at birth and postnatal endocrine and metabolic changes associated with type 2 diabetes. <i>Diabetologia</i> , 2005 , 48, 2661-6	10.3	102
331	Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate?. <i>Value in Health</i> , 2010 , 13, 487-94	3.3	99
330	Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction. <i>Circulation</i> , 2009 , 120, 2429-37	16.7	99
329	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2017 , 2, 370-380	16.2	98
328	Thyocyte HLA-DR expression and interferon-gamma production in autoimmune thyroid disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986 , 63, 695-708	5.6	98
327	Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 168-75	5.6	95
326	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. <i>Circulation</i> , 2020 , 142, 621-642	16.7	88
325	Association of depression with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial. <i>JAMA Psychiatry</i> , 2013 , 70, 1041-7	14.5	88
324	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2016 , 39, 1186-201	14.6	86
323	Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. <i>Diabetes Care</i> , 2014 , 37, 634-43	14.6	86
322	Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. <i>Kidney International</i> , 2004 , 65, 1375-80	9.9	84
321	Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. <i>European Heart Journal</i> , 2015 , 36, 1454-62	9.5	83
320	Diabetes risk among overweight and obese metabolically healthy young adults. <i>Diabetes Care</i> , 2014 , 37, 2989-95	14.6	83
319	Users' Guides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 1995 , 273, 1610	27.4	83
318	Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. <i>Diabetes Care</i> , 2015 , 38, 793-800	14.6	82
317	Acarbose in the treatment of elderly patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2003 , 59, 37-42	7.4	81
316	Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. <i>Diabetes Care</i> , 2016 , 39, 1089-100	14.6	80

315	Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. <i>Circulation</i> , 2011 , 123, 342-8	16.7	80
314	Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. <i>Nature Metabolism</i> , 2019 , 1, 1202-1208	14.6	80
313	Relationship of epicardial fat thickness and fasting glucose. <i>International Journal of Cardiology</i> , 2008 , 128, 424-6	3.2	79
312	Cardiovascular and Renal Outcomes with Efglenatide in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021 , 385, 896-907	59.2	79
311	Diabetes susceptibility. <i>Cmaj</i> , 2006 , 174, 1598-1598	3.5	78
310	Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. <i>Canadian Journal of Cardiology</i> , 2010 , 26, 297-302	3.8	77
309	The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression. <i>Molecular Psychiatry</i> , 2013 , 18, 1281-6	15.1	75
308	Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 612-9	15.1	75
307	The economic cost of diabetes in Canada, 1998. <i>Diabetes Care</i> , 2002 , 25, 1303-7	14.6	74
306	Penetrance of Polygenic Obesity Susceptibility Loci across the Body Mass Index Distribution. <i>American Journal of Human Genetics</i> , 2017 , 101, 925-938	11	73
305	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015 , 169, 631-638.e7	4.9	72
304	Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. <i>Diabetes Care</i> , 2013 , 36, 1266-71	14.6	71
303	Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. <i>Circulation</i> , 2010 , 121, 1176-87	16.7	71
302	Maternal nicotine exposure increases oxidative stress in the offspring. <i>Free Radical Biology and Medicine</i> , 2008 , 44, 1919-25	7.8	71
301	The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. <i>Diabetes Care</i> , 2004 , 27, 2767	14.6	70
300	The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. <i>Diabetes Care</i> , 2014 , 37, 1360-6	14.6	67
299	Troglitazone Monotherapy Improves Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 3169-3176	5.6	67
298	Toward Fairness in Data Sharing. <i>New England Journal of Medicine</i> , 2016 , 375, 405-7	59.2	67

297	Risk Prediction for Early CKD in Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 1371-9	6.9	66
296	Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. <i>Lancet Diabetes and Endocrinology,the</i> , 2018 , 6, 798-808	18.1	66
295	Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: a subanalysis of the ORIGIN trial. <i>International Journal of Cardiology</i> , 2014 , 174, 458-61	3.2	64
294	Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. <i>Respiratory Medicine</i> , 2012 , 106, 1487-93	4.6	64
293	Fetal and neonatal nicotine exposure and postnatal glucose homeostasis: identifying critical windows of exposure. <i>Journal of Endocrinology</i> , 2007 , 194, 171-8	4.7	64
292	Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007 , 45, 1180-5	5.9	63
291	Diagnostic strategies to detect glucose intolerance in a multiethnic population. <i>Diabetes Care</i> , 2003 , 26, 290-6	14.6	63
290	A family-based intervention to promote healthy lifestyles in an aboriginal community in Canada. <i>Canadian Journal of Public Health</i> , 2007 , 98, 447-52	3.2	62
289	Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. <i>American Journal of Kidney Diseases</i> , 2003 , 42, 936-42	7.4	62
288	Do sulphonylureas still have a place in clinical practice?. <i>Lancet Diabetes and Endocrinology,the</i> , 2018 , 6, 821-832	18.1	61
287	Growth Differentiation Factor 15 as a Novel Biomarker for Metformin. <i>Diabetes Care</i> , 2017 , 40, 280-283	14.6	60
286	Cardiometabolic Health in Adults Born Premature With Extremely Low Birth Weight. <i>Pediatrics</i> , 2016 , 138,	7.4	60
285	Association of hematological parameters with insulin resistance and beta-cell dysfunction in nondiabetic subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3824-32	5.6	58
284	Spectrum of quality of life impairment in hypothyroidism. <i>Quality of Life Research</i> , 1994 , 3, 323-7	3.7	58
283	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. <i>Lancet Diabetes and Endocrinology,the</i> , 2021 , 9, 653-662	18.1	58
282	Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. <i>European Journal of Preventive Cardiology</i> , 2012 , 19, 755-64	3.9	57
281	Increased pancreatic beta-cell apoptosis following fetal and neonatal exposure to nicotine is mediated via the mitochondria. <i>Toxicological Sciences</i> , 2008 , 103, 362-70	4.4	57
280	Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. <i>Kidney International</i> , 2004 , S59-62	9.9	56

279	Real-world studies no substitute for RCTs in establishing efficacy. <i>Lancet, The</i> , 2019 , 393, 210-211	40	56
278	Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial. <i>Diabetes Care</i> , 2015 , 38, 22-8	14.6	55
277	BMI at Age 17 Years and Diabetes Mortality in Midlife: A Nationwide Cohort of 2.3 Million Adolescents. <i>Diabetes Care</i> , 2016 , 39, 1996-2003	14.6	55
276	Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. <i>Diabetes Care</i> , 1996 , 19, 1225-8	14.6	55
275	Fetal and neonatal nicotine exposure in Wistar rats causes progressive pancreatic mitochondrial damage and beta cell dysfunction. <i>PLoS ONE</i> , 2008 , 3, e3371	3.7	55
274	Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. <i>Diabetes/Metabolism Research and Reviews</i> , 2002 , 18 Suppl 3, S82-5	7.5	55
273	ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial. <i>Diabetologia</i> , 2017 , 60, 69-80	10.3	54
272	Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. <i>Journal of Hypertension</i> , 2013 , 31, 414-21	1.9	52
271	Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. <i>Kidney International</i> , 2015 , 87, 784-91	9.9	50
270	Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study. <i>Scientific Reports</i> , 2016 , 6, 18672	4.9	50
269	Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. <i>Journal of Lipid Research</i> , 2009 , 50, 1487-96	6.3	50
268	Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). <i>Journal of the American College of Cardiology</i> , 2009 , 53, 2028-35	15.1	50
267	Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. <i>Circulation</i> , 2015 , 132, 2297-304	16.7	49
266	Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>Diabetes Care</i> , 2009 , 32, 915-20	14.6	49
265	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. <i>Lancet Neurology, The</i> , 2020 , 19, 582-590	24.1	48
264	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). <i>Diabetes Care</i> , 2016 , 39, 709-16	14.6	48
263	Does insulin therapy promote, reduce, or have a neutral effect on cancers?. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 303, 446-7	27.4	48
262	Cardiovascular risk in patients with mild renal insufficiency. <i>Kidney International</i> , 2003 , S192-6	9.9	48

261	Establishing a relationship between prolactin and altered fatty acid oxidation via carnitine palmitoyl transferase 1 in breast cancer cells. <i>BMC Cancer</i> , 2011 , 11, 56	4.8	47
260	The relationship between dysglycemia and atherosclerosis in South Asian, Chinese, and European individuals in Canada: a randomly sampled cross-sectional study. <i>Diabetes Care</i> , 2003 , 26, 144-9	14.6	47
259	Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. <i>American Heart Journal</i> , 2014 , 168, 23-9.e2	4.9	46
258	Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	45
257	Combined intensive blood pressure and glycemc control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. <i>Kidney International</i> , 2012 , 81, 586-94	9.9	45
256	Transgenerational effects of fetal and neonatal exposure to nicotine. <i>Endocrine</i> , 2007 , 31, 254-9		45
255	Causal relationship between adiponectin and metabolic traits: a Mendelian randomization study in a multiethnic population. <i>PLoS ONE</i> , 2013 , 8, e66808	3.7	44
254	Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study. <i>Diabetes Research and Clinical Practice</i> , 2007 , 78, 254-8	7.4	44
253	The cross-sectional and longitudinal associations of diabetic retinopathy with cognitive function and brain MRI findings: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <i>Diabetes Care</i> , 2014 , 37, 3244-52	14.6	43
252	Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. <i>Diabetes Care</i> , 2010 , 33, 608-13	14.6	43
251	Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. <i>Diabetologia</i> , 2012 , 55, 36-45	10.3	42
250	Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. <i>Diabetes Care</i> , 2013 , 36, 2162-8	14.6	42
249	Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. <i>Diabetologia</i> , 2010 , 53, 2509-17	10.3	42
248	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 106-114	18.1	42
247	Cognitive function and the risk for diabetes among young men. <i>Diabetes Care</i> , 2014 , 37, 2982-8	14.6	41
246	Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. <i>Diabetologia</i> , 2011 , 54, 487-95	10.3	40
245	Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 300-310	15.1	39
244	Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. <i>Diabetologia</i> , 2014 , 57, 1325-31	10.3	39

243	Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. <i>JAMA Ophthalmology</i> , 2010 , 128, 312-8		39
242	Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 562-72	18.1	37
241	Psychiatric symptoms, bone density and non-specific symptoms in patients with mild hypercalcemia due to primary hyperparathyroidism: a systematic overview of the literature. <i>Endocrine Journal</i> , 1997 , 44, 367-74	2.9	37
240	Prospective association of 25(OH)D with metabolic syndrome. <i>Clinical Endocrinology</i> , 2014 , 80, 502-7	3.4	36
239	Adolescent Obesity and Early-Onset Type 2 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 1487-1495	14.6	36
238	Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). <i>Diabetes Care</i> , 2013 , 36, 2466-74	14.6	35
237	Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. <i>Quality of Life Research</i> , 2011 , 20, 939-43	3.7	35
236	Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. <i>Canadian Journal of Physiology and Pharmacology</i> , 1999 , 77, 118-123	2.4	35
235	Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individuals. <i>Human Molecular Genetics</i> , 2015 , 24, 3582-94	5.6	34
234	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. <i>European Heart Journal</i> , 2014 , 35, 2242-8a	9.5	34
233	Why don't pigs get diabetes? Explanations for variations in diabetes susceptibility in human populations living in a diabetogenic environment. <i>Cmaj</i> , 2006 , 174, 25-6	3.5	34
232	Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial. <i>European Heart Journal</i> , 2020 , 41, 2668-2677 ⁵	9.5	33
231	White blood cell subtypes, insulin resistance and Ecell dysfunction in high-risk individuals--the PROMISE cohort. <i>Clinical Endocrinology</i> , 2014 , 81, 536-41	3.4	33
230	Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. <i>Diabetic Medicine</i> , 2010 , 27, 175-80	3.5	33
229	Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. <i>Diabetes Care</i> , 2016 , 39, 1915-1924	14.6	32
228	Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. <i>Diabetes Care</i> , 2010 , 33, 2250-3	14.6	32
227	Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. <i>Diabetes Research and Clinical Practice</i> , 2007 , 78, 392-7	7.4	31
226	Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. <i>Diabetes Care</i> , 2000 , 23, 377-80	14.6	31

225	Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2013 , 1, 71-8	18.1	30
224	Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial. <i>Diabetic Medicine</i> , 2014 , 31, 1086-92	3.5	30
223	Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) study. <i>Schizophrenia Research</i> , 2007 , 96, 215-22	3.6	30
222	Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. <i>International Journal of Clinical Practice</i> , 2012 , 66, 457-64	2.9	29
221	Shared electronic vascular risk decision support in primary care: Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness (COMPETE III) randomized trial. <i>Archives of Internal Medicine</i> , 2011 , 171, 1736-44		28
220	Incidence of diabetes following ramipril or rosiglitazone withdrawal. <i>Diabetes Care</i> , 2011 , 34, 1265-9	14.6	28
219	Obesity genes and risk of major depressive disorder in a multiethnic population: a cross-sectional study. <i>Journal of Clinical Psychiatry</i> , 2015 , 76, e1611-8	4.6	28
218	How common is postpartum thyroiditis? A methodologic overview of the literature. <i>Archives of Internal Medicine</i> , 1990 , 150, 1397-1400		28
217	The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators. <i>Canadian Journal of Cardiology</i> , 1998 , 14, 1349-57	3.8	28
216	Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1299-1304 ²⁷	6.7	27
215	A controlled evaluation of a national continuing medical education programme designed to improve family physicians' implementation of diabetes-specific clinical practice guidelines. <i>Diabetic Medicine</i> , 1999 , 16, 964-9	3.5	26
214	Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. <i>American Heart Journal</i> , 2015 , 170, 117-22	4.9	25
213	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. <i>Circulation</i> , 2020 , 141, 843-862	16.7	25
212	Hyperglycaemia is associated with impaired vasa vasorum neovascularization and accelerated atherosclerosis in apolipoprotein-E deficient mice. <i>Atherosclerosis</i> , 2013 , 227, 250-8	3.1	25
211	Effects of rosiglitazone on ovarian function and fertility in animals with reduced fertility following fetal and neonatal exposure to nicotine. <i>Endocrine</i> , 2009 , 36, 281-90	4	25
210	Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. <i>American Heart Journal</i> , 2009 , 157, 763-70	4.9	25
209	Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154000 Individuals. <i>Journal of the American Heart Association</i> , 2020 , 9, e014686	6	24
208	Does genetic heterogeneity account for the divergent risk of type 2 diabetes in South Asian and white European populations?. <i>Diabetologia</i> , 2014 , 57, 2270-81	10.3	24

207	More insights on the dysglycaemia-cardiovascular connection. <i>Lancet, The</i> , 2010 , 375, 2195-6	40	24
206	Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. <i>Canadian Family Physician</i> , 2008 , 54, 550-8	0.9	24
205	Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme. <i>Diabetes Research and Clinical Practice</i> , 2009 , 83, 387-93	7.4	23
204	Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. <i>Annals of Clinical Psychiatry</i> , 2018 , 30, 38-50	1.4	23
203	Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1596-1605	5.6	22
202	Lack of association between type 2 diabetes and major depression: epidemiologic and genetic evidence in a multiethnic population. <i>Translational Psychiatry</i> , 2015 , 5, e618	8.6	22
201	Preventing type 2 diabetes using combination therapy: design and methods of the CANadian Normoglycaemia Outcomes Evaluation (CANOE) trial. <i>Diabetes, Obesity and Metabolism</i> , 2006 , 8, 531-7	6.7	22
200	Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. <i>American Journal of Cardiovascular Drugs</i> , 2002 , 2, 157-62	4	22
199	Searching for answers to ethnic disparities in cardiovascular risk. <i>Lancet, The</i> , 2000 , 356, 266-7	40	22
198	Short leg length, a marker of early childhood deprivation, is associated with metabolic disorders underlying type 2 diabetes: the PROMISE cohort study. <i>Diabetes Care</i> , 2013 , 36, 3599-606	14.6	21
197	Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes. <i>Diabetologia</i> , 2010 , 53, 1322-30	10.3	21
196	Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth. <i>Diabetes, Obesity and Metabolism</i> , 2008 , 10, 763-71	6.7	21
195	Reevaluation by high-performance liquid chromatography: clinical significance of microalbuminuria in individuals at high risk of cardiovascular disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>American Journal of Kidney Diseases</i> , 2006 , 48, 889-96	7.4	21
194	Genetic information and the prediction of incident type 2 diabetes in a high-risk multiethnic population: the EpiDREAM genetic study. <i>Diabetes Care</i> , 2013 , 36, 2836-42	14.6	20
193	Dysglycemia and a history of reproductive risk factors. <i>Diabetes Care</i> , 2008 , 31, 1635-8	14.6	20
192	Perceived exertion with glucose ingestion in adolescent males with IDDM. <i>Medicine and Science in Sports and Exercise</i> , 2000 , 32, 167-73	1.2	20
191	Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention). <i>Circulation</i> , 2018 , 137, 88-90	16.7	19
190	Changes in trabecular bone microarchitecture in postmenopausal women with and without type 2 diabetes: a two year longitudinal study. <i>BMC Musculoskeletal Disorders</i> , 2013 , 14, 114	2.8	19

189	Maturation of CGM and Glycemic Measurements Beyond HbA-A Turning Point in Research and Clinical Decisions. <i>Diabetes Care</i> , 2017 , 40, 1611-1613	14.6	18
188	Dysglycemia and cardiovascular risk in the general population. <i>Circulation</i> , 2009 , 119, 773-5	16.7	18
187	Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial. <i>Diabetes Care</i> , 2012 , 35, 749-53	14.6	18
186	Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. <i>European Heart Journal Supplements</i> , 2003 , 5, A43-A48	1.5	18
185	The HOPE study and diabetes. <i>Lancet, The</i> , 2000 , 355, 1183-1184	40	18
184	Diabetes: Dysglycaemia as a cause of cardiovascular outcomes. <i>Nature Reviews Endocrinology</i> , 2015 , 11, 508-10	15.2	17
183	Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study: a randomized noninferiority trial. <i>Diabetes Care</i> , 2014 , 37, 604-10	14.6	17
182	Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. <i>American Heart Journal</i> , 2008 , 156, 1074-9	4.9	17
181	Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries. <i>JAMA Internal Medicine</i> , 2021 , 181, 631-649	11.5	17
180	What accounts for ethnic differences in newborn skinfold thickness comparing South Asians and White Caucasians? Findings from the START and FAMILY Birth Cohorts. <i>International Journal of Obesity</i> , 2016 , 40, 239-44	5.5	16
179	Migliitol, an α -glucosidase inhibitor, prevents the metformin-induced fall in serum folate and vitamin B12 in subjects with type 2 diabetes. <i>Nutrition Research</i> , 2000 , 20, 1447-1456	4	16
178	Summary of randomized trials of angiotensin converting enzyme inhibitors. <i>Clinical and Experimental Hypertension</i> , 1999 , 21, 835-45	2.2	16
177	ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. <i>Diabetes Care</i> , 2020 , 43, 835-842	14.6	16
176	Cognitive function in adolescence and the risk for premature diabetes and cardiovascular mortality in adulthood. <i>Cardiovascular Diabetology</i> , 2018 , 17, 154	8.7	16
175	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. <i>Diabetes Care</i> , 2018 , 41, 2404-2413	14.6	16
174	Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity. <i>Canadian Journal of Cardiology</i> , 2003 , 19, 1387-91	3.8	16
173	Coronary artery disease risk among obese metabolically healthy young men. <i>European Journal of Endocrinology</i> , 2015 , 173, 305-12	6.5	15
172	Effect of hypoglycemia on brain structure in people with type 2 diabetes: epidemiological analysis of the ACCORD-MIND MRI trial. <i>Diabetes Care</i> , 2014 , 37, 3279-85	14.6	15

171	Causes and consequences of gestational diabetes in South Asians living in Canada: results from a prospective cohort study. <i>CMAJ Open</i> , 2017 , 5, E604-E611	2.5	15
170	Optimizing the methodology for measuring supraclavicular skin temperature using infrared thermography; implications for measuring brown adipose tissue activity in humans. <i>Scientific Reports</i> , 2017 , 7, 11934	4.9	15
169	Telomere Length and Risk of Myocardial Infarction in a MultiEthnic Population: The INTERHEART Study. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1863-1865	15.1	15
168	Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial. <i>Diabetes Care</i> , 2019 , 42, 142-147	14.6	15
167	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Diabetes Care</i> , 2021 ,	14.6	15
166	Antenatal exposure to the selective serotonin reuptake inhibitor fluoxetine leads to postnatal metabolic and endocrine changes associated with type 2 diabetes in Wistar rats. <i>Toxicology and Applied Pharmacology</i> , 2015 , 285, 32-40	4.6	14
165	Blood HER2 and Uromodulin as Causal Mediators of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 1326-1335	12.7	14
164	Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. <i>Diabetic Medicine</i> , 2010 , 27, 1226-325	3.5	14
163	Dysglycemia and the Density of the Coronary Vasa Vasorum. <i>Diabetes Care</i> , 2019 , 42, 980-982	14.6	13
162	Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. <i>American Journal of Hypertension</i> , 2015 , 28, 995-1009	2.3	13
161	Increased cardiovascular risk after pre-eclampsia in women with dysglycaemia. <i>Diabetic Medicine</i> , 2013 , 30, e1-7	3.5	13
160	Comment on Hempe et al. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. <i>Diabetes Care</i> 2015;38:1067-1074. <i>Diabetes Care</i> , 2015 , 38, e170-1	14.6	13
159	Cognitive Performance at Late Adolescence and the Risk for Impaired Fasting Glucose Among Young Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 4409-16	5.6	13
158	Maternal antioxidants prevent β cell apoptosis and promote formation of dual hormone-expressing endocrine cells in male offspring following fetal and neonatal nicotine exposure. <i>Journal of Diabetes</i> , 2012 , 4, 297-306	3.8	13
157	Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation?. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005 , 34, 137-54	5.5	13
156	Dysglycemia: a key cardiovascular risk factor. <i>Seminars in Vascular Medicine</i> , 2002 , 2, 165-74		13
155	HbA Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. <i>Diabetes Care</i> , 2021 , 44, 290-296	14.6	13
154	Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. <i>Journal of Diabetes Research</i> , 2018 , 2018, 1631263	3.9	13

153	Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. <i>Diabetes</i> , 2020 , 69, 771-783	0.9	12
152	Glycemic index predicts individual glucose responses after self-selected breakfasts in free-living, abdominally obese adults. <i>Journal of Nutrition</i> , 2012 , 142, 27-32	4.1	12
151	Piloting a novel algorithm for glucose control in the coronary care unit: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) trial. <i>Diabetes Care</i> , 2012 , 35, 19-24	14.6	12
150	Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. <i>Diabetes Care</i> , 2021 , 44, 164-173	14.6	12
149	Sleep quality and risk of diabetes and coronary artery disease among young men. <i>Acta Diabetologica</i> , 2016 , 53, 261-70	3.9	11
148	Can community retail pharmacist and diabetes expert support facilitate insulin initiation by family physicians? Results of the AIM@GP randomized controlled trial. <i>BMC Health Services Research</i> , 2013 , 13, 71	2.9	11
147	Basal insulin and cardiovascular and other outcomes. <i>New England Journal of Medicine</i> , 2012 , 367, 1761-2; author reply 1763-4	59.2	11
146	Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood. <i>Diabetes Care</i> , 2020 , 43, 145-151	14.6	11
145	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. <i>American Journal of Medicine</i> , 2017 , 130, 1465.e27-1465.e39	2.4	10
144	Is regression to normoglycaemia clinically important?. <i>Lancet, The</i> , 2012 , 379, 2216-8	40	10
143	Postnatal metabolic and reproductive consequences of fetal and neonatal exposure to the smoking cessation drug bupropion. <i>Reproductive Sciences</i> , 2013 , 20, 1156-61	3	10
142	Dysglycaemia: a cardiovascular risk factor. <i>Diabetes Research and Clinical Practice</i> , 1998 , 40 Suppl, S9-14	7.4	10
141	Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study. <i>Diabetes Care</i> , 2020 , 43, 3094-3101	14.6	10
140	Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. <i>Diabetes Care</i> , 2018 , 41, 348-355	14.6	10
139	Validation of the ORIGIN Cardiovascular Biomarker Panel and the Value of Adding Troponin I in Dysglycemic People. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2251-2257	5.6	9
138	Item reduction and validation of the Chinese version of diabetes quality-of-life measure (DQOL). <i>Health and Quality of Life Outcomes</i> , 2018 , 16, 78	3	9
137	Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 790-797	18.1	9
136	Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. <i>Diabetologia</i> , 2014 , 57, 2030-7	10.3	9

135	Effect of computer-generated tailored feedback on glycemic control in people with diabetes in the community: a randomized controlled trial. <i>Diabetes Care</i> , 2011 , 34, 1794-8	14.6	9
134	A new mutation in the thyroid hormone receptor (TR) beta gene (V458A) in a family with resistance to thyroid hormone (RTH). <i>Thyroid</i> , 1996 , 6, 311-2	6.2	9
133	Separate induction of MHC and thyroid microsomal antigen (McAg) expression on thyroid cell monolayers: enhancement of lectin-induced McAg expression by interferon-gamma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987 , 64, 1302-8	5.6	9
132	Vascular Regenerative Cell Exhaustion in Diabetes: Translational Opportunities to Mitigate Cardiometabolic Risk. <i>Trends in Molecular Medicine</i> , 2019 , 25, 640-655	11.5	8
131	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. <i>European Journal of Heart Failure</i> , 2020 , 22, 1133-1143	12.3	8
130	Influence of Genetic Ancestry on Human Serum Proteome. <i>American Journal of Human Genetics</i> , 2020 , 106, 303-314	11	8
129	Impact of a computerized system for evidence-based diabetes care on completeness of records: a before-after study. <i>BMC Medical Informatics and Decision Making</i> , 2012 , 12, 63	3.6	8
128	Is it possible to reduce cardiovascular risk with glucose-lowering approaches?. <i>Nature Reviews Endocrinology</i> , 2009 , 5, 270-5	15.2	8
127	Epidemiologic analyses of risk factors, risk indicators, risk markers, and causal factors. The example of albuminuria and the risk of cardiovascular disease in diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2002 , 31, 537-51	5.5	8
126	Effects of lifelong testosterone exposure on health and disease using Mendelian randomization. <i>ELife</i> , 2020 , 9,	8.9	8
125	A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of Disease. <i>Clinical Chemistry</i> , 2019 , 65, 427-436	5.5	8
124	Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 318-323	6.7	8
123	The Cardiovascular Legacy of Good Glycemic Control: Clues About Mediators From the DCCT/EDIC Study. <i>Diabetes Care</i> , 2019 , 42, 1159-1161	14.6	7
122	The Genetic Link Between Diabetes and Atherosclerosis. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 565-573	3.8	7
121	Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI. <i>Diabetologia</i> , 2014 , 57, 738-45	10.3	7
120	Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial. <i>Blood Pressure</i> , 2014 , 23, 54-60	1.7	7
119	The Relationship between Intramuscular Adipose Tissue, Functional Mobility, and Strength in Postmenopausal Women with and without Type 2 Diabetes. <i>Journal of Aging Research</i> , 2015 , 2015, 872726	2.3	7
118	Evaluating the feasibility and impact of an internet-based lifestyle management program in a diabetes care setting. <i>Diabetes Technology and Therapeutics</i> , 2014 , 16, 358-62	8.1	7

117	Randomized trial of insulin versus usual care in reducing restenosis after coronary intervention in patients with diabetes. the STent Restenosis And Metabolism (STREAM) study. <i>Cardiovascular Revascularization Medicine</i> , 2012 , 13, 95-100	1.6	7
116	The effects of exercise training on insulin resistance in patients with coronary artery disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007 , 14, 803-8		7
115	Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial. <i>Diabetic Medicine</i> , 2004 , 21, 1200-3	3.5	7
114	Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. <i>Circulation</i> , 2021 ,	16.7	7
113	Are large simple trials for dementia prevention possible?. <i>Age and Ageing</i> , 2020 , 49, 154-160	3	7
112	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. <i>European Heart Journal</i> , 2021 , 42, 2565-2573	9.5	7
111	Consensus report: definition and interpretation of remission in type 2 diabetes. <i>Diabetologia</i> , 2021 , 64, 2359-2366	10.3	7
110	Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation.. <i>Nature Genetics</i> , 2022 ,	36.3	7
109	Systematic review: Can non-mydiatic cameras accurately detect diabetic retinopathy?. <i>Diabetes Research and Clinical Practice</i> , 2017 , 129, 154-159	7.4	6
108	Insulin resistance and cardiovascular outcomes in the ORIGIN trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 564-570	6.7	6
107	Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial. <i>Journal of Diabetes and Its Complications</i> , 2014 , 28, 553-8	3.2	6
106	Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 2682-9	5.6	6
105	Preventive medicine in a diabetes clinic: an opportunity to make a difference. <i>Lancet, The</i> , 1999 , 353, 606-8	40	6
104	Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 847-854	3.9	6
103	The Relationship Between the Score on a Simple Measure of Cognitive Function and Incident CVD in People With Diabetes: A Post Hoc Epidemiological Analysis From the ACCORD-MIND Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 3218-3225	5.6	5
102	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017 , 136, 1560-1562	16.7	5
101	The importance of randomised vs non-randomised trials - Authors' reply. <i>Lancet, The</i> , 2019 , 394, 635	40	5
100	Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	5

99	Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population. <i>Journal of Diabetes</i> , 2011 , 3, 232-7	3.8	5
98	Dysglycaemia, dyslipidaemia and hypertension: risk factors primarily focused on the disease or risk estimates primarily focused on the patient?. <i>Diabetologia</i> , 2011 , 54, 230-2	10.3	5
97	Rosiglitazone improves pancreatic mitochondrial function in an animal model of dysglycemia: role of the insulin-like growth factor axis. <i>Endocrine</i> , 2010 , 37, 303-11	4	5
96	Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points. <i>Diabetes and Vascular Disease Research</i> , 2008 , 5, 276-84	3.3	5
95	Insulin Therapy: The Discovery That Shaped a Century. <i>Canadian Journal of Diabetes</i> , 2021 ,	2.1	5
94	Association Between Bariatric Surgery and Major Adverse Diabetes Outcomes in Patients With Diabetes and Obesity. <i>JAMA Network Open</i> , 2021 , 4, e216820	10.4	5
93	Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e34-e44	5.6	5
92	Influence of depression on genetic predisposition to type 2 diabetes in a multiethnic longitudinal study. <i>Scientific Reports</i> , 2017 , 7, 1629	4.9	4
91	Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. <i>Diabetes Care</i> , 2020 , 43, 2242-2247	14.6	4
90	Identification of Circulating Proteins Associated With Blood Pressure Using Mendelian Randomization. <i>Circulation Genomic and Precision Medicine</i> , 2020 , 13, e002605	5.2	4
89	Newly diagnosed type 2 diabetes may serve as a potential marker for pancreatic cancer. <i>Diabetes/Metabolism Research and Reviews</i> , 2018 , 34, e3018	7.5	4
88	Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. <i>American Heart Journal</i> , 2018 , 199, 170-175	4.9	4
87	Longitudinal relationships between glycemic status and body mass index in a multiethnic study: evidence from observational and genetic epidemiology. <i>Scientific Reports</i> , 2016 , 6, 30744	4.9	4
86	Dosage recommendations for combination regimen of thyroxine and 3,5,3'-triiodothyronine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 1486-7; author reply 1487-8	5.6	4
85	Cardiovascular Outcomes and Renal Disease. <i>Annals of Internal Medicine</i> , 2002 , 136, 634	8	4
84	Sensitization of T lymphocytes to thyroid antigen in autoimmune thyroid disease as demonstrated by the monocyte procoagulant activity test. <i>Journal of Endocrinological Investigation</i> , 1986 , 9, 471-8	5.2	4
83	Individualized electronic decision support and reminders can improve diabetes care in the community 2005 , 982	0.7	4
82	Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial.. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021 , 16, 102382	8.9	4

81	Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young Adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e3426-e3435	5.6	4
80	Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents. <i>Diabetes Care</i> , 2021 , 44, e6-e8	14.6	4
79	The Relationship Between Glucose Control and Cognitive Function in People With Diabetes After a Lacunar Stroke. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e1521-e1528	5.6	4
78	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	4
77	Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. <i>Cardiovascular Diabetology</i> , 2021 , 20, 194	8.7	4
76	Self-Perceived Emotional Distress and Diabetes Risk Among Young Men. <i>American Journal of Preventive Medicine</i> , 2016 , 50, 737-745	6.1	3
75	Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk. <i>Diabetes Care</i> , 2019 , 42, 1800-1808	14.6	3
74	Clinical benefits and adverse effects of genetically-elevated free testosterone levels: a Mendelian randomization analysis		3
73	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trial: a post hoc analysis. <i>Cardiovascular Diabetology</i> , 2020 , 19, 199	8.7	3
72	The Diabetes Health Coaching Randomized Controlled Trial: Rationale, Design and Baseline Characteristics of Adults Living With Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2019 , 43, 477-482	2.1	3
71	Diabetes, Brain Infarcts, Cognition, and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e891-e898	5.6	3
70	The plasma glucose level—a continuous risk factor for vascular disease in both diabetic and non-diabetic people. <i>Advances in Experimental Medicine and Biology</i> , 2001 , 498, 35-9	3.6	3
69	The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial. <i>Diabetes and Vascular Disease Research</i> , 2017 , 14, 345-352	3.3	2
68	Minimally important difference and predictors of change in quality of life in type 2 diabetes: A community-based survey in China. <i>Diabetes/Metabolism Research and Reviews</i> , 2018 , 34, e3053	7.5	2
67	Effect of combining rosiglitazone with either metformin or insulin on β cell mass and function in an animal model of Type 2 diabetes characterized by reduced β cell mass at birth. <i>Journal of Diabetes</i> , 2011 , 3, 74-81	3.8	2
66	Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?. <i>Cmaj</i> , 2006 , 174, 1090-3	5.3	2
65	Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007 , 3, 798-9		2
64	A disturbed glucose metabolic state (dysglycaemia) is a key risk factor for cardiovascular events. <i>European Heart Journal Supplements</i> , 2003 , 5, B1-B2	1.5	2

63	The burden of treatment failure in type 2 diabetes: response to Brown et al. <i>Diabetes Care</i> , 2005 , 28, 761-2	14.6	2
62	Immunomodulatory effect of the treatment of Graves' disease on antigen-specific monocyte procoagulant activity production. <i>Clinical Endocrinology</i> , 1987 , 27, 321-30	3.4	2
61	Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes.. <i>Diabetes Care</i> , 2022 ,	14.6	2
60	Neighborhood Walkability and Diabetes-Related Complications. <i>Diabetes</i> , 2018 , 67, 309-OR	0.9	2
59	356-OR: Effect of Dulaglutide on Kidney Function Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial. <i>Diabetes</i> , 2020 , 69, 356-OR	0.9	2
58	Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial. <i>Diabetologia</i> , 2022 , 65, 206-215	10.3	2
57	Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. <i>Frontiers in Genetics</i> , 2016 , 7, 138	4.5	2
56	The association of basal insulin treatment versus standard care with outcomes in anti-GAD positive and negative subjects: A post-hoc analysis of the ORIGIN trial. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 429-433	6.7	2
55	Stuttering and Incident Type 2 Diabetes: A Population-Based Study of 2.2 Million Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 978-987	5.6	2
54	Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 1345-1351	5.6	2
53	Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018 , 47, 97-116	5.5	2
52	Consensus report: Definition and interpretation of remission in type 2 diabetes. <i>Diabetic Medicine</i> , 2021 , e14669	3.5	2
51	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2021 , 9, 484-490	18.1	2
50	Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2021 , 10, e022222	6.2	2
49	Identification of genetic effects underlying type 2 diabetes in South Asian and European populations.. <i>Communications Biology</i> , 2022 , 5, 329	6.7	2
48	Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> 2016;39:1186-1201. <i>Diabetes Care</i> , 2017 , 40, e23-e24	14.6	1
47	Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INTERvention (ORIGIN) trial. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1502-1505	6.7	1
46	Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials. <i>Lancet Diabetes and Endocrinology,the</i> , 2020 , 8, 557-558	18.1	1

45	Setting the record straight on TIDE: a lost opportunity for patients with diabetes. <i>Diabetologia</i> , 2013 , 56, 1884-7	10.3	1
44	Willingness to take drugs to prevent serious chronic diseases. <i>Journal of Diabetes</i> , 2014 , 6, 76-80	3.8	1
43	A community-based approach for the self-management of diabetes. <i>European Diabetes Nursing</i> , 2011 , 8, 54-59		1
42	Long-acting risperidone and oral antipsychotics in schizophrenia. <i>New England Journal of Medicine</i> , 2011 , 364, 2265; author reply 265-6	59.2	1
41	Reply to comment on: Gerstein HC, Pogue J, Mann JFE et al. (2005) The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. <i>Diabetologia</i> 48:1749-1755. <i>Diabetologia</i> , 2006 , 49, 613-614	10.3	1
40	Authors' Response: Dosage Recommendations for Combination Regimen of Thyroxine and 3,5,3',5'-Tetraiodothyronine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 1487-1487	5.6	1
39	The value of large, robust trials: the HOPE study. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2002 , 19, 29-30		1
38	924-P: Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND. <i>Diabetes</i> , 2020 , 69, 924-P	0.9	1
37	Novel Biomarkers for Change in Renal Function in People With Dysglycemia. <i>Diabetes Care</i> , 2020 , 43, 433-439	14.6	1
36	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. <i>Cardiovascular Diabetology</i> , 2020 , 19, 175	8.7	1
35	Effect of Diabetes Health Coaching on Glycemic Control and Quality of Life in Adults Living With Type 2 Diabetes: A Community-Based, Randomized, Controlled Trial. <i>Canadian Journal of Diabetes</i> , 2021 , 45, 594-600	2.1	1
34	Testosterone and sex hormone-binding globulin in dysglycemic women at high cardiovascular risk: A report from the Outcome Reduction with an Initial Glargine Intervention trial. <i>Diabetes and Vascular Disease Research</i> , 2021 , 18, 14791641211002475	3.3	1
33	NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia - A brief report from the ORIGIN trial. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107928	3.2	1
32	Making a Difference With Diabetes Research and Care. <i>Diabetes Care</i> , 2016 , 39, 1309-10	14.6	1
31	Exploring the Experiences of Adults With Type 2 Diabetes on Sodium Glucose Cotransporter 2 Inhibitors. <i>Canadian Journal of Diabetes</i> , 2020 , 44, 184-191	2.1	1
30	Adolescent cognitive function and incident early-onset type 2 diabetes. <i>EClinicalMedicine</i> , 2021 , 41, 101138	13.8	1
29	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes.. <i>Journal of the American Heart Association</i> , 2022 , e021327	6	1
28	Response to Suissa and Azoulay. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. <i>Diabetes Care</i> 2014;37:1360-1366. <i>Diabetes Care</i> , 2014 , 37, e217	14.6	0

27	Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes (RESET-IT Main): A 2-year randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1926-1935	6.7	o
26	Asthma in Youth and Early-onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e5043-e5053	5.6	o
25	Creating Composite Indices From Continuous Variables for Research: The Geometric Mean. <i>Diabetes Care</i> , 2021 , 44, e85-e86	14.6	o
24	Effects of intensive glycaemic control on ischaemic heart disease - Authors' reply. <i>Lancet, The</i> , 2015 , 385, 1180-1	40	
23	Dulaglutide slows kidney disease in type 2 diabetes - Author's reply. <i>Lancet, The</i> , 2020 , 395, 559-560	40	
22	In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events. <i>Annals of Internal Medicine</i> , 2018 , 168, JC53	8	
21	Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics. <i>Endocrinología y Nutrición (English Ed)</i> , 2019 , 66, 467-468	0.1	
20	Microvascular outcomes in type 2 diabetes - Authors' reply. <i>Lancet Diabetes and Endocrinology, the</i> , 2017 , 5, 580	18.1	
19	Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial. <i>Diabetes Research and Clinical Practice</i> , 2017 , 132, 137-143	7.4	
18	Response to Zanders et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. <i>Diabetes Care</i> 2014;37:1360-1366. <i>Diabetes Care</i> , 2014 , 37, e223	14.6	
17	Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C . <i>Diabetes Care</i> , 2013 , 36, e181	14.6	
16	Macular Edema and ThiazolidinedionesReply. <i>JAMA Ophthalmology</i> , 2010 , 128, 1631		
15	Ramipril slowed the decline in renal function among patients with nephropathy and proteinuria not due to insulin-dependent diabetes mellitus. <i>Evidence-based Cardiovascular Medicine</i> , 1998 , 2, 23-24		
14	Fußeschwelle bei Diabetes. <i>Vasa - European Journal of Vascular Medicine</i> , 2001 , 30, 233-237	1.9	
13	Glycemia and Risk for Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2005 , 142, 227	8	
12	240-LB: Angiotensin-Converting Enzyme and Type 2 Diabetes Risk: A Mendelian Randomization Study. <i>Diabetes</i> , 2019 , 68, 240-LB	0.9	
11	1506-P: Breast Cancer as a Risk Factor for New Diabetes. <i>Diabetes</i> , 2019 , 68, 1506-P	0.9	
10	254-OR: Novel Biomarkers Predicting Renal Dysfunction in People with Dysglycemia in the ORIGIN Trial. <i>Diabetes</i> , 2019 , 68, 254-OR	0.9	

9	Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics. <i>Endocrinologia, Diabetes Y Nutrición</i> , 2019 , 66, 467-468	1.3
8	130-OR: Effects of Intensive Risk Factor Management on Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: Findings from the ACCORD Trial. <i>Diabetes</i> , 2020 , 69, 130-OR	0.9
7	944-P: HbA1c Change Is Associated with Retinopathy Outcomes during GLP-1RA CVOT Follow-Up. <i>Diabetes</i> , 2020 , 69, 944-P	0.9
6	187-OR: Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes in the ACCORD Trial. <i>Diabetes</i> , 2021 , 70, 187-OR	0.9
5	Insulin use for type 2 diabetes: the challenges of predicting trends and modelling care. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 4-5	18.1
4	Enalapril reduced the risk for developing new-onset diabetes in left ventricular dysfunction. <i>ACP Journal Club</i> , 2003 , 139, 68	
3	Intensive insulin therapy reduced cardiovascular disease in type 1 diabetes. <i>ACP Journal Club</i> , 2006 , 144, 63	
2	Shouldn't Preventing Type 2 Diabetes Also Prevent Its Long-Term Consequences?. <i>Circulation</i> , 2022 , 145, 1642-1644	16.7
1	Response to Comment on Koska et al. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. <i>Diabetes Care</i> 2022;44:6848-91. <i>Diabetes Care</i> , 2022 , 45, e111-e112	14.6